Cytori Receives Key Cell Therapy Patent For Scleroderma
Published: Jul 06, 2017
Strengthens Global Scleroderma Intellectual Property Portfolio
Extends E.U. protection through 2034
SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) announced today the issuance of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has 107 global patents issued and another 45 patent applications pending around the globe. Several of Cytori’s recently issued patents contain claims covering the use of Habeo™ Cell Therapy for patients with scleroderma affecting the hands.
- On July 5, 2017 the European Patent Office (EPO) issued Patent No. 3046417, which claims the use of Adipose-Derived Regenerative Cells (ADRCs), including Cytori’s Habeo™ Cell Therapy for scleroderma, including treatment of Raynaud’s Phenomenon or suppression of pain from Raynaud’s Phenomenon. This patent has a term at least through 2034.
- On April 19, 2017, the EPO issued Patent No. 1670315, which claims the use of ADRCs, including Cytori’s Habeo™ Cell Therapy, to treat vascular diseases, which are disorders that affect the blood carrying vessels of the body. Vascular disease is a very common complication in patients with scleroderma where it can contribute to digital ulcers and other problems. This patent has a term at least through 2024 and covers the use of Habeo™ Cell Therapy for vascular diseases, including but not limited to disease associated with scleroderma.
- On December 6, 2016, the U.S. Patent Office issued Patent No. 9511096, which claims the use of ADRCs, including Cytori Cell Therapy™, to treat ischemic wounds. This patent has a term at least through December 2022 and covers the use of Habeo™ Cell Therapy for treatment of digital ulcers in scleroderma patients.
"Building on Cytori’s broad intellectual property portfolio continues to be a priority," said John D. Harris, Vice President and General Manager, Cell Therapy. "Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy™ platform to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary therapeutic targets of scleroderma and Raynaud’s Phenomenon, though we will continue to seek additional intellectual property in other therapeutic areas as well."
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the pointofcare through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing liposome encapsulated therapies for regenerative medicine and oncologic indications. For more information, please visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements, including statements regarding projected patent terms, Cytori’s patent strategy and areas of interest, and potential uses of Cytori’s patent portfolio to support its product pipeline, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include risks related to protection and enforcement of our intellectual property portfolio such as risks regarding infringing or competing third party intellectual property, risks that our intellectual property may infringe other intellectual property rights (or may be at risk of challenge or invalidation), or risks that the claims in our patents and patent applications may not be granted, may be successfully challenged ,or may be insufficient in coverage or scope to support and achieve our corporate objectives, and other risks and uncertainties described under the "Risk Factors" in Cytori’s Securities and Exchange Commission Filings, included in our annual and quarterly reports.
There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities.
Cytori Therapeutics, Inc. Tiago Girao, 1-858-458-0900 firstname.lastname@example.org